Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM, Spotbeen X, Bagadi M, Waltregny D, Moldovan M, Dehairs J, Vanderhoydonc F, Bloch K, Das R, Stahl J, Kench JG, Gevaert T, Derua R, Waelkens E, Nassar ZD, Selth LA, Trim PJ, Snel MF, Lynn DJ, Tilley WD, Horvath LG, Centenera MM, Swinnen JV. Butler LM, et al. Among authors: gevaert t. Cancer Res. 2021 Oct 1;81(19):4981-4993. doi: 10.1158/0008-5472.CAN-20-3863. Epub 2021 Aug 6. Cancer Res. 2021. PMID: 34362796
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Tosco L, Laenen A, Gevaert T, Salmon I, Decaestecker C, Davicioni E, Buerki C, Claessens F, Swinnen J, Goffin K, Oyen R, Everaerts W, Moris L, De Meerleer G, Haustermans K, Joniau S; P.E.A.R.L. (ProstatE cAncer Research Leuven). Tosco L, et al. Among authors: gevaert t. BMC Cancer. 2018 Apr 2;18(1):354. doi: 10.1186/s12885-018-4275-z. BMC Cancer. 2018. PMID: 29606109 Free PMC article.
Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer.
Van den Broeck T, Moris L, Gevaert T, Davicioni E, Boeckx B, Lambrechts D, Helsen C, Handle F, Ghesquière B, Soenen S, Smeets E, Eerlings R, El Kharraz S, Devlies W, Karnes RJ, Lotan T, Van Poppel H, Joniau S, Claessens F. Van den Broeck T, et al. Among authors: gevaert t. Mol Cancer Res. 2022 Apr 1;20(4):527-541. doi: 10.1158/1541-7786.MCR-21-0388. Mol Cancer Res. 2022. PMID: 35082164
DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer.
Litovkin K, Van Eynde A, Joniau S, Lerut E, Laenen A, Gevaert T, Gevaert O, Spahn M, Kneitz B, Gramme P, Helleputte T, Isebaert S, Haustermans K, Bollen M. Litovkin K, et al. Among authors: gevaert o, gevaert t. PLoS One. 2015 Jun 18;10(6):e0130651. doi: 10.1371/journal.pone.0130651. eCollection 2015. PLoS One. 2015. PMID: 26086362 Free PMC article.
Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.
Gevaert T, Montironi R, Lopez-Beltran A, Van Leenders G, Allory Y, De Ridder D, Claessens F, Kockx M, Akand M, Joniau S, Netto G, Libbrecht L. Gevaert T, et al. Semin Cancer Biol. 2018 Oct;52(Pt 2):216-227. doi: 10.1016/j.semcancer.2017.10.004. Epub 2017 Oct 12. Semin Cancer Biol. 2018. PMID: 29032188 Review.
Current and emerging therapies for localized high-risk prostate cancer.
Moris L, Devos G, Van den Broeck T, Milonas D, Albersen M, Berghen C, De Meerleer G, Devlies W, Everaerts W, Gevaert T, Van Poppel H, Claessens F, Joniau S. Moris L, et al. Among authors: gevaert t. Expert Rev Anticancer Ther. 2021 Mar;21(3):267-282. doi: 10.1080/14737140.2021.1852932. Epub 2020 Dec 22. Expert Rev Anticancer Ther. 2021. PMID: 33225759 Review.
142 results